48 results
8-K
EX-99.1
SVRA
Savara Inc
5 Jan 24
Regulation FD Disclosure
8:00am
oxygenation that Reduced oxygen delivery makes it hard to breath and, oxygen delivery ultimately, hypoxemic respiratory Air-filled alveolus Surfactant-filled … Measures how well oxygen ▪ O saturation must be stable passes from the air sacs of 2 before assessment (≤2% points the lungs into the blood over 5 min.) Can
8-K
EX-1.1
SVRA
Savara Inc
13 Jul 23
Savara Announces Pricing of $80 Million Underwritten Offering of Common
5:18pm
to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface
424B5
SVRA
Savara Inc
13 Jul 23
Prospectus supplement for primary offering
5:17pm
the addressable market by two to four times its current size.
aPAP is characterized by the accumulation of surfactant in the alveoli, or air sacs … in the alveoli (or air sacs) of the lungs. The estimated prevalence of aPAP is seven cases per million people in the U.S. The disease process underlying aPAP
8-K
EX-99.1
SVRA
Savara Inc
8 Jun 23
Regulation FD Disclosure
4:20pm
alveolar macrophage Air-filled alveolus Surfactant-filled alveolus
© Savara Inc. All Rights Reserved. aPAP is a Rare, Long-Term, Chronic Disease
8-K
EX-10.1
bdzcbyfdqfwy2b
4 Jun 21
Entry into a Material Definitive Agreement
7:51am
424B5
sh5eln3o
12 Mar 21
Prospectus supplement for primary offering
6:06am
8-K
EX-1.1
1d0j10c5j
11 Mar 21
Savara Announces Pricing of Public Offering of Common Stock
5:14pm
424B5
m46czq
10 Mar 21
Prospectus supplement for primary offering
4:32pm
8-K
EX-10.1
rkcp08rq6r2sqhuzvf
20 Dec 19
Savara Announces Private Placement of $26.8 Million, with Total Potential Proceeds of $75.0 Million
5:23pm
8-K
EX-10.2
7y6hutha9 ac9gd8g7q
20 Dec 19
Savara Announces Private Placement of $26.8 Million, with Total Potential Proceeds of $75.0 Million
5:23pm
8-K
EX-99.1
2uoxq9688mc
2 Oct 19
Regulation FD Disclosure
8:11am